Rani Therapeutics Announces Successful Oral Delivery Of Monoclonal Antibody Via High-Capacity Pill In Preclinical Study
Portfolio Pulse from Happy Mohamed
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) announced successful oral delivery of a monoclonal antibody, Humira® (adalimumab), via its high-capacity capsule, the RaniPill® HC, in a preclinical study. The RaniPill® HC has achieved a cumulative >90% success rate across multiple preclinical studies. The company has been shortlisted as a finalist in the 2023 Fierce Life Sciences Innovation Awards in the 'Drug Delivery Technology' category.
October 19, 2023 | 8:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rani Therapeutics' successful preclinical study of the RaniPill HC for oral delivery of Humira and its nomination for the Fierce Life Sciences Innovation Awards could positively impact its stock.
The successful preclinical study of RaniPill HC indicates progress in Rani Therapeutics' product development, which could increase investor confidence and drive the stock price up. Additionally, the company's nomination for the Fierce Life Sciences Innovation Awards could enhance its reputation in the industry, potentially attracting more investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100